Status:
COMPLETED
Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
Lead Sponsor:
Ospedale Microcitemico
Collaborating Sponsors:
Azienda Sanitaria Locale di Cagliari
Conditions:
Iron Overload
Cardiomyopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major (TM). Therapy with deferoxamine (DFO) combined with deferiprone (DFP) reduces myocardial iron and improve...
Eligibility Criteria
Inclusion
- Cardiomyopathy secondary to iron overload
Exclusion
- Heart failure
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00800761
Start Date
December 1 2001
End Date
June 1 2006
Last Update
December 2 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Adult Talassemic Center, Ospedale Microcitemico
Cagliari, Sardinia, Italy, 09121